FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL					
	OMB Number:	3235-0287					
	Estimated average burden						
	hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) 123 SAC	23 SAGINAW DRIVE				2. Issuer Name and Ticker or Trading Symbol AP PHARMA INC /DE/ [APPA] 3. Date of Earliest Transaction (Month/Day/Year) 01/15/2008							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) VP of Clinical Development			
(Street) REDWC CITY (City)	X		94063 (Zip)	_	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 5)					4. Securi Disposed 5) Amount	ties Acqui	or Price	or 4 and Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 5. Amount of Securities Form: Direct (D) or Indirect (I) (Instr. 4) 6. Ownership Form: Direct (I) (Instr. 4) 7. Nature of Indirect (I) (Instr. 4) 7. Nature of Indirect (I) (Instr. 4)		of Indirect Beneficial Ownership					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	(e.g., 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)	action	5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	oer ve es ed ed ed	Expiration Date (Month/Day/Year) (Month/Day/Year) Lunderlying Derivative Security (Ir and 4)		and t of ies ving ive	8. Price of Derivative Security (Instr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Incentive Stock Option (Right to Buy) ⁽¹⁾	\$1.37	01/15/2008		A		72,992		01/14/2012	01/14/2018	72,992	72,992	\$1.37	72,992	D	
Non- Qualified Stock Option (Right to Buy) ⁽¹⁾	\$1.37	01/15/2008		A		41,708		01/14/2012	01/14/2018	41,708	41,708	\$1.37	41,708	D	

Explanation of Responses:

1. Stock Option Grant vests over four year period in increments of 2.0833% per month.

Remarks:

Calvin Reuter for Anastassios Retzios

01/17/2008

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these present, that the undersigned hereby constitutes and appoints Michael O'Connell, Juan Shen or Calvin Reuter, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of A.P. Pharma, Inc., Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of October, 2007.

/s/ Anastassios Retzios Signature

Anastassios Retzios Printed Name